ABBV
AbbVie Inc.
Price Chart
Latest Quote
$225.64
Current Price| Previous Close | $223.01 |
| Open | $224.85 |
| Day High | $229.78 |
| Day Low | $224.44 |
| Volume | 5,383,257 |
Stock Information
| Quarterly Dividend / Yield | $6.65 / 2.98% |
| Shares Outstanding | 1.77B |
| Total Debt | $68.85B |
| Cash Equivalents | $5.67B |
| Revenue | $59.64B |
| Net Income | $2.35B |
| Sector | Healthcare |
| Industry | Drug Manufacturers - General |
| Market Cap | $398.79B |
| P/E Ratio | 170.94 |
| EPS (TTM) | $1.32 |
| Exchange | NYQ |
📊 Custom Metrics & Score
Score: 9/42| Debt to Equity | 20.19 |
| Debt to Earnings | 1.70 |
| Current Ratio | 0.66 |
| Quick Ratio | 0.43 |
| Avg Revenue Growth | 0.06% |
| Profit Margin | 7.59% |
| Return on Equity | 128.66% |
| Avg FCF Growth | -4.73% |
| FCF Yield | 4.47% |
Score Explanation: The perfect score is 42/42 based on debt levels, profitability, growth rates, and cash flow metrics. FCF Yield is weighted most heavily as it shows what return the business currently generates.
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-02-02 | $225.64 | 5,387,226 |
| 2026-01-30 | $223.01 | 6,622,200 |
| 2026-01-29 | $220.43 | 7,834,000 |
| 2026-01-28 | $218.67 | 5,215,800 |
| 2026-01-27 | $223.93 | 5,747,400 |
| 2026-01-26 | $220.77 | 6,553,400 |
| 2026-01-23 | $219.26 | 5,816,400 |
| 2026-01-22 | $218.11 | 5,650,900 |
| 2026-01-21 | $216.15 | 10,727,100 |
| 2026-01-20 | $214.04 | 8,251,400 |
| 2026-01-16 | $214.35 | 8,649,700 |
| 2026-01-15 | $215.02 | 6,954,200 |
| 2026-01-14 | $220.12 | 8,426,400 |
| 2026-01-13 | $218.99 | 4,872,600 |
| 2026-01-12 | $218.28 | 6,546,100 |
| 2026-01-09 | $218.32 | 6,714,200 |
| 2026-01-08 | $222.34 | 9,365,900 |
| 2026-01-07 | $231.56 | 10,285,400 |
| 2026-01-06 | $222.14 | 9,151,700 |
| 2026-01-05 | $218.42 | 9,341,300 |
About AbbVie Inc.
AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacture, commercialization, and sale of medicines and therapies worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, generalized pustular psoriasis, and pyoderma gangrenosum; Skyrizi to treat autoimmune diseases, erythrodermic psoriasis, generalized pustular psoriasis, and palmoplantar pustulosis; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta/Venclyxto to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic to treat neurologic diseases; Vraylar to treat schizophrenia, bipolar disorder, and depressive disorder; Duopa and Duodopa to treat Parkinson's disease; Ubrelvy to treat migraine; and Qulipta for episodic and chronic migraine, as well as other neuroscience products. In addition, the company offers Ozurdex for eye diseases; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Restasis to increase tear production; and other eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; and Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation. AbbVie Inc. has strategic partnership with OSE Immunotherapeutics. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
📰 Latest News
January jobs data, Alphabet and Amazon earnings, more Warsh fallout: What to watch this week
Yahoo Finance • 2026-02-01T12:47:23ZBig Tech and Pharma Earnings: What to Watch This Week
The Wall Street Journal • 2026-02-02T23:02:23Z
Assessing AbbVie (ABBV) Valuation After Mixed Short Term Share Price Performance
Simply Wall St. • 2026-02-02T20:12:04Z
Market Awaits January Manufacturing Numbers
Zacks • 2026-02-02T16:12:00Z
Six More Weeks of Q4 Earnings Season?
Zacks • 2026-02-02T15:35:00Z
Buy AbbVie Stock Before Q4 Earnings? Here's What to Know
Zacks • 2026-02-02T15:34:00Z
Where Will AbbVie Be in 5 Years?
Motley Fool • 2026-02-02T09:05:00Z
AbbVie’s US$100b Drug Pricing Pact Reshapes Growth And Policy Outlook
Simply Wall St. • 2026-02-01T17:08:51Z
2 No-Brainer Dividend Stocks to Buy Hand Over Fist
Motley Fool • 2026-02-01T11:13:00Z
AbbVie Inc. (ABBV) Balances Analyst Caution with Pipeline Progress and Long-Term Growth
Insider Monkey • 2026-01-31T14:35:53Z
Income Statement (Annual)
Revenue
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Reconciled Cost Of Revenue | $16,904,000,000 | $20,415,000,000 | $17,414,000,000 | $17,446,000,000 |
| Cost Of Revenue | $16,904,000,000 | $20,415,000,000 | $17,414,000,000 | $17,446,000,000 |
| Total Revenue | $56,334,000,000 | $54,318,000,000 | $58,054,000,000 | $56,197,000,000 |
| Operating Revenue | $56,334,000,000 | $54,318,000,000 | $58,054,000,000 | $56,197,000,000 |
Expenses
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Interest Expense | $2,808,000,000 | $2,224,000,000 | $2,230,000,000 | $2,423,000,000 |
| Total Expenses | $44,440,000,000 | $40,783,000,000 | $39,240,000,000 | $38,273,000,000 |
| Other Income Expense | $-6,018,000,000 | $-5,601,000,000 | $-3,293,000,000 | $-2,551,000,000 |
| Other Non Operating Income Expenses | $-3,240,000,000 | $-4,677,000,000 | $-2,448,000,000 | $-2,500,000,000 |
| Net Non Operating Interest Income Expense | $-2,160,000,000 | $-1,684,000,000 | $-2,044,000,000 | $-2,384,000,000 |
| Interest Expense Non Operating | $2,808,000,000 | $2,224,000,000 | $2,230,000,000 | $2,423,000,000 |
| Operating Expense | $27,536,000,000 | $20,368,000,000 | $21,826,000,000 | $20,827,000,000 |
| Other Operating Expenses | $-7,000,000 | $-179,000,000 | $56,000,000 | $432,000,000 |
Income & Earnings
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Net Income From Continuing Operation Net Minority Interest | $4,278,000,000 | $4,863,000,000 | $11,836,000,000 | $11,542,000,000 |
| Net Interest Income | $-2,160,000,000 | $-1,684,000,000 | $-2,044,000,000 | $-2,384,000,000 |
| Interest Income | $648,000,000 | $540,000,000 | $186,000,000 | $39,000,000 |
| Normalized Income | $6,472,620,000 | $5,583,720,000 | $12,578,755,000 | $11,587,339,000 |
| Net Income From Continuing And Discontinued Operation | $4,278,000,000 | $4,863,000,000 | $11,836,000,000 | $11,542,000,000 |
| Total Operating Income As Reported | $9,137,000,000 | $12,757,000,000 | $18,117,000,000 | $17,924,000,000 |
| Net Income Common Stockholders | $4,238,000,000 | $4,820,000,000 | $11,782,000,000 | $11,468,000,000 |
| Net Income | $4,278,000,000 | $4,863,000,000 | $11,836,000,000 | $11,542,000,000 |
| Net Income Including Noncontrolling Interests | $4,286,000,000 | $4,873,000,000 | $11,845,000,000 | $11,549,000,000 |
| Net Income Continuous Operations | $4,286,000,000 | $4,873,000,000 | $11,845,000,000 | $11,549,000,000 |
| Pretax Income | $3,716,000,000 | $6,250,000,000 | $13,477,000,000 | $12,989,000,000 |
| Special Income Charges | $-2,757,000,000 | $-778,000,000 | $-697,000,000 | $-1,124,000,000 |
| Interest Income Non Operating | $648,000,000 | $540,000,000 | $186,000,000 | $39,000,000 |
| Operating Income | $11,894,000,000 | $13,535,000,000 | $18,814,000,000 | $17,924,000,000 |
| Gross Profit | $39,430,000,000 | $33,903,000,000 | $40,640,000,000 | $38,751,000,000 |
Per Share Metrics
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Diluted EPS | $2.39 | $2.72 | $6.63 | $6.45 |
| Basic EPS | $2.42 | $2.75 | $6.69 | $6.53 |
Other
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Tax Effect Of Unusual Items | $-583,380,000 | $-203,280,000 | $-102,245,000 | $-5,661,000 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $17,688,000,000 | $18,096,000,000 | $25,019,000,000 | $23,984,000,000 |
| Total Unusual Items | $-2,778,000,000 | $-924,000,000 | $-845,000,000 | $-51,000,000 |
| Total Unusual Items Excluding Goodwill | $-2,778,000,000 | $-924,000,000 | $-845,000,000 | $-51,000,000 |
| Reconciled Depreciation | $8,386,000,000 | $8,698,000,000 | $8,467,000,000 | $8,521,000,000 |
| EBITDA (Bullshit earnings) | $14,910,000,000 | $17,172,000,000 | $24,174,000,000 | $23,933,000,000 |
| EBIT | $6,524,000,000 | $8,474,000,000 | $15,707,000,000 | $15,412,000,000 |
| Diluted Average Shares | $1,773,000,000 | $1,773,000,000 | $1,778,000,000 | $1,777,000,000 |
| Basic Average Shares | $1,765,256,986 | $1,765,940,733 | $1,769,181,294 | $1,768,337,696 |
| Diluted NI Availto Com Stockholders | $4,238,000,000 | $4,820,000,000 | $11,782,000,000 | $11,468,000,000 |
| Otherunder Preferred Stock Dividend | $40,000,000 | $43,000,000 | $54,000,000 | $74,000,000 |
| Minority Interests | $-8,000,000 | $-10,000,000 | $-9,000,000 | $-7,000,000 |
| Tax Provision | $-570,000,000 | $1,377,000,000 | $1,632,000,000 | $1,440,000,000 |
| Other Special Charges | $2,757,000,000 | $778,000,000 | $697,000,000 | $1,124,000,000 |
| Gain On Sale Of Security | $-21,000,000 | $-146,000,000 | $-148,000,000 | $-51,000,000 |
| Research And Development | $12,791,000,000 | $7,675,000,000 | $6,510,000,000 | $8,046,000,000 |
| Selling General And Administration | $14,752,000,000 | $12,872,000,000 | $15,260,000,000 | $12,349,000,000 |
Balance Sheet (Annual)
Assets
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Net Tangible Assets | $-91,699,000,000 | $-77,543,000,000 | $-82,341,000,000 | $-92,922,000,000 |
| Total Assets | $135,161,000,000 | $134,711,000,000 | $138,805,000,000 | $146,529,000,000 |
| Total Non Current Assets | $109,579,000,000 | $101,709,000,000 | $110,342,000,000 | $118,601,000,000 |
| Other Non Current Assets | $9,142,000,000 | $8,513,000,000 | $5,571,000,000 | $4,884,000,000 |
| Goodwill And Other Intangible Assets | $95,024,000,000 | $87,903,000,000 | $99,595,000,000 | $108,330,000,000 |
| Other Intangible Assets | $60,068,000,000 | $55,610,000,000 | $67,439,000,000 | $75,951,000,000 |
| Current Assets | $25,582,000,000 | $33,002,000,000 | $28,463,000,000 | $27,928,000,000 |
| Other Current Assets | $4,927,000,000 | $4,932,000,000 | $4,401,000,000 | $4,993,000,000 |
| Inventory | $4,181,000,000 | $4,099,000,000 | $3,579,000,000 | $3,128,000,000 |
| Receivables | $10,919,000,000 | $11,155,000,000 | $11,254,000,000 | $9,977,000,000 |
| Accounts Receivable | $10,919,000,000 | $11,155,000,000 | $11,254,000,000 | $9,977,000,000 |
| Cash Cash Equivalents And Short Term Investments | $5,555,000,000 | $12,816,000,000 | $9,229,000,000 | $9,830,000,000 |
| Cash And Cash Equivalents | $5,524,000,000 | $12,814,000,000 | $9,201,000,000 | $9,746,000,000 |
| Prepaid Assets | - | - | - | $4,993,000,000 |
Debt
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Net Debt | $61,620,000,000 | $46,571,000,000 | $54,070,000,000 | $66,938,000,000 |
| Total Debt | $67,144,000,000 | $59,385,000,000 | $63,271,000,000 | $76,684,000,000 |
| Long Term Debt And Capital Lease Obligation | $60,340,000,000 | $52,194,000,000 | $59,135,000,000 | $64,189,000,000 |
| Long Term Debt | $60,340,000,000 | $52,194,000,000 | $59,135,000,000 | $64,189,000,000 |
| Current Debt And Capital Lease Obligation | $6,804,000,000 | $7,191,000,000 | $4,136,000,000 | $12,495,000,000 |
| Current Debt | $6,804,000,000 | $7,191,000,000 | $4,136,000,000 | $12,495,000,000 |
Liabilities
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Total Liabilities Net Minority Interest | $131,797,000,000 | $124,314,000,000 | $121,518,000,000 | $131,093,000,000 |
| Total Non Current Liabilities Net Minority Interest | $93,048,000,000 | $86,473,000,000 | $91,980,000,000 | $95,899,000,000 |
| Other Non Current Liabilities | $27,634,000,000 | $28,607,000,000 | $26,032,000,000 | $22,106,000,000 |
| Tradeand Other Payables Non Current | $1,261,000,000 | $2,182,000,000 | $2,985,000,000 | $3,442,000,000 |
| Non Current Deferred Liabilities | $2,579,000,000 | $1,952,000,000 | $2,190,000,000 | $3,009,000,000 |
| Non Current Deferred Taxes Liabilities | $2,579,000,000 | $1,952,000,000 | $2,190,000,000 | $3,009,000,000 |
| Current Liabilities | $38,749,000,000 | $37,841,000,000 | $29,538,000,000 | $35,194,000,000 |
| Payables And Accrued Expenses | $31,945,000,000 | $30,650,000,000 | $25,402,000,000 | $22,699,000,000 |
| Payables | $5,881,000,000 | $6,471,000,000 | $5,614,000,000 | $5,425,000,000 |
| Dividends Payable | $2,936,000,000 | $2,783,000,000 | $2,680,000,000 | $2,543,000,000 |
| Accounts Payable | $2,945,000,000 | $3,688,000,000 | $2,934,000,000 | $2,882,000,000 |
Equity
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Common Stock Equity | $3,325,000,000 | $10,360,000,000 | $17,254,000,000 | $15,408,000,000 |
| Total Equity Gross Minority Interest | $3,364,000,000 | $10,397,000,000 | $17,287,000,000 | $15,436,000,000 |
| Stockholders Equity | $3,325,000,000 | $10,360,000,000 | $17,254,000,000 | $15,408,000,000 |
| Gains Losses Not Affecting Retained Earnings | $-1,925,000,000 | $-2,305,000,000 | $-2,199,000,000 | $-2,899,000,000 |
| Other Equity Adjustments | $-1,925,000,000 | $-2,305,000,000 | $-2,199,000,000 | $-2,899,000,000 |
| Retained Earnings | $-7,900,000,000 | $-1,000,000,000 | $4,784,000,000 | $3,127,000,000 |
Other
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Treasury Shares Number | $66,337,508 | $57,105,354 | $44,589,000 | $34,857,597 |
| Ordinary Shares Number | $1,765,256,986 | $1,765,940,733 | $1,769,181,294 | $1,768,337,696 |
| Share Issued | $1,831,594,494 | $1,823,046,087 | $1,813,770,294 | $1,803,195,293 |
| Tangible Book Value | $-91,699,000,000 | $-77,543,000,000 | $-82,341,000,000 | $-92,922,000,000 |
| Invested Capital | $70,469,000,000 | $69,745,000,000 | $80,525,000,000 | $92,092,000,000 |
| Working Capital | $-13,167,000,000 | $-4,839,000,000 | $-1,075,000,000 | $-7,266,000,000 |
| Total Capitalization | $63,665,000,000 | $62,554,000,000 | $76,389,000,000 | $79,597,000,000 |
| Minority Interest | $39,000,000 | $37,000,000 | $33,000,000 | $28,000,000 |
| Treasury Stock | $8,201,000,000 | $6,533,000,000 | $4,594,000,000 | $3,143,000,000 |
| Additional Paid In Capital | $21,333,000,000 | $20,180,000,000 | $19,245,000,000 | $18,305,000,000 |
| Capital Stock | $18,000,000 | $18,000,000 | $18,000,000 | $18,000,000 |
| Common Stock | $18,000,000 | $18,000,000 | $18,000,000 | $18,000,000 |
| Employee Benefits | $1,234,000,000 | $1,538,000,000 | $1,638,000,000 | $3,153,000,000 |
| Non Current Pension And Other Postretirement Benefit Plans | $1,234,000,000 | $1,538,000,000 | $1,638,000,000 | $3,153,000,000 |
| Current Accrued Expenses | $26,064,000,000 | $24,179,000,000 | $19,788,000,000 | $17,274,000,000 |
| Investments And Advances | $279,000,000 | $304,000,000 | $241,000,000 | $277,000,000 |
| Goodwill | $34,956,000,000 | $32,293,000,000 | $32,156,000,000 | $32,379,000,000 |
| Net PPE | $5,134,000,000 | $4,989,000,000 | $4,935,000,000 | $5,110,000,000 |
| Accumulated Depreciation | $-7,133,000,000 | $-6,646,000,000 | $-6,051,000,000 | $-5,617,000,000 |
| Gross PPE | $12,267,000,000 | $11,635,000,000 | $10,986,000,000 | $10,727,000,000 |
| Construction In Progress | $1,093,000,000 | $1,073,000,000 | $856,000,000 | $799,000,000 |
| Machinery Furniture Equipment | $7,995,000,000 | $7,449,000,000 | $7,107,000,000 | $6,850,000,000 |
| Buildings And Improvements | $2,895,000,000 | $2,827,000,000 | $2,737,000,000 | $2,791,000,000 |
| Land And Improvements | $284,000,000 | $286,000,000 | $286,000,000 | $287,000,000 |
| Properties | $0 | $0 | $0 | $0 |
| Finished Goods | $1,173,000,000 | $1,356,000,000 | $1,162,000,000 | $932,000,000 |
| Work In Process | $1,951,000,000 | $1,643,000,000 | $1,417,000,000 | $1,193,000,000 |
| Raw Materials | $1,057,000,000 | $1,100,000,000 | $1,000,000,000 | $1,003,000,000 |
| Other Short Term Investments | $31,000,000 | $2,000,000 | $28,000,000 | $84,000,000 |
Cash Flow Statement (Annual)
Free Cash Flow
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Free Cash Flow | $17,832,000,000 | $22,062,000,000 | $24,248,000,000 | $21,990,000,000 |
Operating Activities
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Operating Cash Flow | $18,806,000,000 | $22,839,000,000 | $24,943,000,000 | $22,777,000,000 |
| Cash Flow From Continuing Operating Activities | $18,806,000,000 | $22,839,000,000 | $24,943,000,000 | $22,777,000,000 |
| Operating Gains Losses | - | - | $-172,000,000 | $-68,000,000 |
Investing Activities
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Capital Expenditure | $-974,000,000 | $-777,000,000 | $-695,000,000 | $-787,000,000 |
| Investing Cash Flow | $-20,820,000,000 | $-2,009,000,000 | $-623,000,000 | $-2,344,000,000 |
| Cash Flow From Continuing Investing Activities | $-20,820,000,000 | $-2,009,000,000 | $-623,000,000 | $-2,344,000,000 |
| Net Other Investing Changes | $189,000,000 | $13,000,000 | $774,000,000 | $366,000,000 |
Financing Activities
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Repurchase Of Capital Stock | $-1,708,000,000 | $-1,972,000,000 | $-1,487,000,000 | $-934,000,000 |
| Financing Cash Flow | $-5,211,000,000 | $-17,222,000,000 | $-24,803,000,000 | $-19,039,000,000 |
| Cash Flow From Continuing Financing Activities | $-5,211,000,000 | $-17,222,000,000 | $-24,803,000,000 | $-19,039,000,000 |
| Net Other Financing Charges | $-42,000,000 | $-742,000,000 | $-1,102,000,000 | $-674,000,000 |
| Cash Dividends Paid | $-11,025,000,000 | $-10,539,000,000 | $-10,043,000,000 | $-9,261,000,000 |
| Common Stock Dividend Paid | $-11,025,000,000 | $-10,539,000,000 | $-10,043,000,000 | $-9,261,000,000 |
| Net Common Stock Issuance | $-1,708,000,000 | $-1,972,000,000 | $-1,487,000,000 | $-934,000,000 |
Other
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Repayment Of Debt | $-14,621,000,000 | $-4,149,000,000 | $-14,433,000,000 | $-9,414,000,000 |
| Issuance Of Debt | $21,971,000,000 | $0 | $2,000,000,000 | $1,000,000,000 |
| Interest Paid Supplemental Data | $2,811,000,000 | $2,469,000,000 | $2,546,000,000 | $2,712,000,000 |
| Income Tax Paid Supplemental Data | $4,064,000,000 | $4,702,000,000 | $2,988,000,000 | $3,648,000,000 |
| End Cash Position | $5,524,000,000 | $12,814,000,000 | $9,201,000,000 | $9,746,000,000 |
| Beginning Cash Position | $12,814,000,000 | $9,201,000,000 | $9,746,000,000 | $8,449,000,000 |
| Effect Of Exchange Rate Changes | $-65,000,000 | $5,000,000 | $-62,000,000 | $-97,000,000 |
| Changes In Cash | $-7,225,000,000 | $3,608,000,000 | $-483,000,000 | $1,394,000,000 |
| Proceeds From Stock Option Exercised | $214,000,000 | $180,000,000 | $262,000,000 | $244,000,000 |
| Common Stock Payments | $-1,708,000,000 | $-1,972,000,000 | $-1,487,000,000 | $-934,000,000 |
| Net Issuance Payments Of Debt | $7,350,000,000 | $-4,149,000,000 | $-12,433,000,000 | $-8,414,000,000 |
| Net Short Term Debt Issuance | $0 | $0 | $0 | $0 |
| Short Term Debt Payments | $-5,008,000,000 | $0 | $0 | $0 |
| Short Term Debt Issuance | $5,008,000,000 | $0 | $0 | - |
| Net Long Term Debt Issuance | $7,350,000,000 | $-4,149,000,000 | $-12,433,000,000 | $-8,414,000,000 |
| Long Term Debt Payments | $-9,613,000,000 | $-4,149,000,000 | $-14,433,000,000 | $-9,414,000,000 |
| Long Term Debt Issuance | $16,963,000,000 | $0 | $2,000,000,000 | $1,000,000,000 |
| Net Investment Purchase And Sale | $482,000,000 | $-22,000,000 | $92,000,000 | $-21,000,000 |
| Sale Of Investment | $555,000,000 | $55,000,000 | $1,530,000,000 | $98,000,000 |
| Purchase Of Investment | $-73,000,000 | $-77,000,000 | $-1,438,000,000 | $-119,000,000 |
| Net Business Purchase And Sale | $-20,517,000,000 | $-1,223,000,000 | $-794,000,000 | $-1,902,000,000 |
| Purchase Of Business | $-20,517,000,000 | $-1,223,000,000 | $-794,000,000 | $-1,902,000,000 |
| Net PPE Purchase And Sale | $-974,000,000 | $-777,000,000 | $-695,000,000 | $-787,000,000 |
| Purchase Of PPE | $-974,000,000 | $-777,000,000 | $-695,000,000 | $-787,000,000 |
| Change In Working Capital | $-2,782,000,000 | $2,813,000,000 | $-94,000,000 | $-1,231,000,000 |
| Change In Other Working Capital | $-3,208,000,000 | $-488,000,000 | $542,000,000 | $-1,290,000,000 |
| Change In Payables And Accrued Expense | $177,000,000 | $3,840,000,000 | $1,769,000,000 | $1,719,000,000 |
| Change In Payable | $177,000,000 | $3,840,000,000 | $1,769,000,000 | $1,719,000,000 |
| Change In Account Payable | $177,000,000 | $3,840,000,000 | $1,769,000,000 | $1,719,000,000 |
| Change In Prepaid Assets | $361,000,000 | $-188,000,000 | $-264,000,000 | $-197,000,000 |
| Change In Inventory | $-319,000,000 | $-417,000,000 | $-686,000,000 | $-142,000,000 |
| Change In Receivables | $207,000,000 | $66,000,000 | $-1,455,000,000 | $-1,321,000,000 |
| Changes In Account Receivables | $207,000,000 | $66,000,000 | $-1,455,000,000 | $-1,321,000,000 |
| Other Non Cash Items | $4,470,000,000 | $4,811,000,000 | $3,144,000,000 | $3,999,000,000 |
| Stock Based Compensation | $911,000,000 | $747,000,000 | $671,000,000 | $692,000,000 |
| Provisionand Write Offof Assets | $508,000,000 | $-443,000,000 | $2,243,000,000 | $163,000,000 |
| Asset Impairment Charge | $4,476,000,000 | $4,229,000,000 | $770,000,000 | $50,000,000 |
| Deferred Tax | $-1,449,000,000 | $-2,889,000,000 | $-1,931,000,000 | $-898,000,000 |
| Deferred Income Tax | $-1,449,000,000 | $-2,889,000,000 | $-1,931,000,000 | $-898,000,000 |
| Depreciation Amortization Depletion | $8,386,000,000 | $8,698,000,000 | $8,467,000,000 | $8,521,000,000 |
| Depreciation And Amortization | $8,386,000,000 | $8,698,000,000 | $8,467,000,000 | $8,521,000,000 |
| Amortization Cash Flow | $7,622,000,000 | $7,946,000,000 | $7,689,000,000 | $7,718,000,000 |
| Amortization Of Intangibles | $7,622,000,000 | $7,946,000,000 | $7,689,000,000 | $7,718,000,000 |
| Depreciation | $764,000,000 | $752,000,000 | $778,000,000 | $803,000,000 |
| Gain Loss On Sale Of Business | $0 | $0 | $-172,000,000 | $-68,000,000 |
| Net Income From Continuing Operations | $4,286,000,000 | $4,873,000,000 | $11,845,000,000 | $11,549,000,000 |